Anti-thymocyte globulin in haematology: Recent developments

Thumbnail Image
Files
ijmr2019v150n3p221.pdf (552.94 KB)
Date
2019-09
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Indian Council of Medical Research
Abstract
Anti-thymocyte globulin (ATG) is a polyclonal antiserum introduced into clinical medicine more than 30 years ago. It induces a broad non-specific immunosuppression. In haematology, standard indications are severe aplastic anaemia and prophylaxis and treatment of graft-versus-host disease (GVHD) (after allogeneic transplantation). For aplastic anaemia, ATG from horses has been found to be superior to ATG from rabbits. In the situation of allogeneic transplantation, ATG lessens the risk of chronic GVHD but may not improve survival. There is current controversy regarding which patients benefit most from ATG and what the ideal dosage is. It is likely that in the coming years a more specific immunosuppressive will be developed that will minimize GVHD while maintaining the graft-versus-malignancy effect.
Description
Keywords
Anti-thymocyte globulin, graft-versus-host disease, immunosuppressive effect, myelodysplastic syndrome, severe aplastic anaemia
Citation
Siddiqui S, Cox J, Herzig R, Palaniyandi S, Hildebrandt GC, Munker R. Anti-thymocyte globulin in haematology: Recent developments. Indian Journal of Medical Research. 2019 Sep; 150(3): 221-227
URI
https://imsear.searo.who.int/handle/123456789/196021
Collections
Indian Journal of Medical Research